CAMP4 Therapeutics Targets First SYNGAP1 Data in 2028 as Patient Dosing Nears
CAMP4 Therapeutics plans to start patient dosing for its SYNGAP1 treatment, CMP-002, by year-end and report initial data in early 2028. The Phase 1/2 trial will evaluate safety and potential efficacy signals, but not establish efficacy. The company has $124.5 million in cash, expected to fund operations through 2028, including the SYNGAP1 readout and other programs.

